Ceftriaxone (Rocephin)

Ceftriaxone (Rocephin)

C difficile risk
Oral Bioavailability


1-2g IV/IM q12-24h

2g IV q12h

No dosage adjustments provided in manufacturer's labeling

However, in patients with concurrent hepatic dysfunction (impaired biliary excretion) and severe kidney impairment, use of doses greater than 2g/day should be done with caution and close monitoring for toxicity

CrCl greater than 15 mL/minCrCl less than or equal to 15 mL/minNo dosing adjustment requiredNo dosage adjustment necessary

However, doses of greater than 2g/day have not been studied and should be done with close monitoring, especially in patients with concurrent hepatic dysfunction (decreased biliary excretion)

General Information

Empiric therapy of:

  • Bacterial meningitis

  •  Nosocomial gram negative infections (except Pseudomonas)

  •  Spontaneous bacterial peritonitis

  •  Hospitalized community or nursing home acquired pneumonia in combination with a macrolide

  • Allergy/rash (immediate or delayed)
  • Cytopenias
  • Eosinophilia
  • Hepatic & renal laboratory abnormalities
  • Pseudocholelithiasis
    • Unclear clinical significance
    • Uncommonly symptomatic, but frequently by ultrasound gallbladder sludge

Antimicrobial class: Parenteral Cephalosporin - 3rd Generation

Pregnancy category: B

Average serum half life: 8 hours

Biliary penetration: Therapeutic

CSF penetration: Therapeutic

Lung penetration: Therapeutic

Urine penetration: Therapeutic